Investor Presentaiton
Next Wave Clinical and Regulatory Progress
VanflytaⓇ (quizartinib) (FLT3-ITD positive acute myeloid leukemia [AML], 1L)
May 2023: Approved in Japan
■■Jul 2023: Approved in US
Ezharmia
(valemetostat) (relapsed/refractory peripheral T-cell lymphoma [PTCL])
Jun 2023: TLR obtained
DS-5670 (COVID-19 mRNA vaccine)
■May 2023: Ph3 study for omicron strain booster vaccination in healthy volunteers 12 years and over
■May 2023: Ph2/3 study for omicron strain booster vaccination in children aged 5 to 11 years.
DS-7011 (systemic lupus erythematosus [SLE])
Jul 2023: Ph1b/2 study for SLE patients started
DS-2325 (Netherton syndrome)
■May 2023: Granted Rare Pediatric Disease Designation by FDA
Daiichi-Sankyo
FDA: U.S. Food and Drug Administration, TLR: top line results
28View entire presentation